$MDT
Medtronic plc Stock $mdt

$mdt Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000161310319000038 Filed on August 30, 2019

Income Statement

Concept	2019 Q3	2018 Q3	2018 Q2
Revenue	$7.493B	$7.384B	$8.144B
YoY Change	1.48%	-0.08%	2.88%
Cost Of Revenue	$2.366B	$2.204B	$2.383B
YoY Change	7.35%	-6.29%	-1.93%
Gross Profit	$5.127B	$5.180B	$5.746B
YoY Change	-1.02%	2.82%	4.85%
Gross Profit Margin	68.42%	70.15%	70.56%
Selling, General & Admin	$2.543B	$2.597B	$2.533B
YoY Change	-2.08%	0.66%	-9.08%
% of Gross Profit	49.6%	50.14%	44.08%
Research & Development	$587.0M	$585.0M	$592.0M
YoY Change	0.34%	6.56%	7.05%
% of Gross Profit	11.45%	11.29%	10.3%
Depreciation & Amortization	$657.0M	$666.0M	$664.0M
YoY Change	-1.35%	4.72%	-7.52%
% of Gross Profit	12.81%	12.86%	11.56%
Operating Expenses	$3.130B	$3.182B	$3.719B
YoY Change	-1.63%	1.69%	-2.97%
Operating Profit	$1.485B	$1.236B	$2.027B
YoY Change	20.15%	-10.56%	23.07%
Interest Expense	$609.0M	$242.0M	-$345.0M
YoY Change	151.65%	-15.38%	200.0%
% of Operating Profit	41.01%	19.58%	-17.02%
Other Income/Expense, Net	$101.0M	$186.0M	$234.0M
YoY Change	-45.7%	-381.82%	-541.51%
Pretax Income	$977.0M	$1.180B	$1.725B
YoY Change	-17.2%	-1.26%	20.21%
Income Tax	$100.0M	$103.0M	$223.0M
% Of Pretax Income	10.24%	8.73%	12.93%
Net Earnings	$864.0M	$1.075B	$1.460B
YoY Change	-19.63%	5.81%	25.54%
Net Earnings / Revenue	11.53%	14.56%	17.93%
Basic Earnings Per Share	$0.64	$0.79	$1.08
Diluted Earnings Per Share	$0.64	$0.79	$1.07
COMMON SHARES
Basic Shares Outstanding	1.341B shares	1.353B shares	1.352B shares
Diluted Shares Outstanding	1.352B shares	1.365B shares

Balance Sheet

Concept	2019 Q3	2018 Q3	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.68B	$11.00B	$11.23B
YoY Change	-2.92%	-15.92%	-18.1%
Cash & Equivalents	$5.080B	$4.380B	$3.669B
Short-Term Investments	$5.603B	$6.624B	$7.558B
Other Short-Term Assets	$2.196B	$2.101B	$2.187B
YoY Change	4.52%	5.05%	17.27%
Inventory	$3.932B	$3.681B	$3.579B
Prepaid Expenses
Receivables	$5.894B	$5.674B	$5.987B
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$22.71B	$22.46B	$22.98B
YoY Change	1.09%	-9.36%	-7.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.711B	$4.524B	$4.604B
YoY Change	4.13%	3.12%	5.57%
Goodwill	$40.08B	$38.96B	$39.54B
YoY Change	2.89%	-0.61%	2.67%
Intangibles	$20.23B	$21.27B	$21.72B
YoY Change	-4.87%	-7.55%	-7.19%
Long-Term Investments	$372.0M	$500.0M	$18.00M
YoY Change	-25.6%	-31.32%
Other Assets	$1.991B	$1.099B	$1.078B
YoY Change	81.16%	-14.41%	-12.5%
Total Long-Term Assets	$68.56B	$67.26B	$68.41B
YoY Change	1.94%	-10.88%	-8.76%
TOTAL ASSETS
Total Short-Term Assets	$22.71B	$22.46B	$22.98B
Total Long-Term Assets	$68.56B	$67.26B	$68.41B
Total Assets	$91.27B	$89.72B	$91.39B
YoY Change	1.72%	-10.5%	-8.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.906B	$1.789B	$1.628B
YoY Change	6.54%	1.71%	4.69%
Accrued Expenses	$4.430B	$4.735B	$5.232B
YoY Change	-6.44%	8.53%	17.76%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.458B	$1.545B	$2.058B
YoY Change	-5.63%	-80.83%	-72.54%
Total Short-Term Liabilities	$8.518B	$9.112B	$10.08B
YoY Change	-6.52%	-39.85%	-29.3%
LONG-TERM LIABILITIES
Long-Term Debt	$24.80B	$23.68B	$23.69B
YoY Change	4.76%	-8.77%	-8.43%
Other Long-Term Liabilities	$1.590B	$801.0M	$889.0M
YoY Change	98.5%	-21.93%	-41.32%
Total Long-Term Liabilities	$1.590B	$801.0M	$24.58B
YoY Change	98.5%	-21.93%	-10.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.518B	$9.112B	$10.08B
Total Long-Term Liabilities	$1.590B	$801.0M	$24.58B
Total Liabilities	$40.77B	$39.39B	$40.57B
YoY Change	3.5%	-20.36%	-18.08%
SHAREHOLDERS EQUITY
Retained Earnings	$26.38B	$24.73B	$24.38B
YoY Change	6.66%	2.86%	4.77%
Common Stock	$0.00	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$50.36B	$50.22B	$50.72B
YoY Change
Total Liabilities & Shareholders Equity	$91.27B	$89.72B	$91.39B
YoY Change	1.72%	-10.5%	-8.48%

Cashflow Statement

Concept	2019 Q3	2018 Q3	2018 Q2
OPERATING ACTIVITIES
Net Income	$864.0M	$1.075B	$1.460B
YoY Change	-19.63%	5.81%	25.54%
Depreciation, Depletion And Amortization	$657.0M	$666.0M	$664.0M
YoY Change	-1.35%	4.72%	-7.52%
Cash From Operating Activities	$1.510B	$1.702B	$1.038B
YoY Change	-11.28%	130.94%	-41.46%
INVESTING ACTIVITIES
Capital Expenditures	$301.0M	$291.0M	-$292.0M
YoY Change	3.44%	4.68%	-11.52%
Acquisitions	$145.0M	$104.0M
YoY Change	39.42%
Other Investing Activities	$5.000M	$0.00	$403.0M
YoY Change		-100.0%	594.83%
Cash From Investing Activities	-$551.0M	$643.0M	$111.0M
YoY Change	-185.69%	674.7%	-140.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$333.0M	$824.0M
YoY Change	-59.59%	-33.17%
Debt Paid & Issued, Net	$5.035B	$12.00M
YoY Change	41858.33%	50.0%
Cash From Financing Activities	-$274.0M	-$1.573B	-3.828B
YoY Change	-82.58%	37.86%	-657.21%
NET CHANGE
Cash From Operating Activities	$1.510B	$1.702B	1.038B
Cash From Investing Activities	-$551.0M	$643.0M	111.0M
Cash From Financing Activities	-$274.0M	-$1.573B	-3.828B
Net Change In Cash	$687.0M	$772.0M	-2.679B
YoY Change	-11.01%	-340.5%	-222.44%
FREE CASH FLOW
Cash From Operating Activities	$1.510B	$1.702B	$1.038B
Capital Expenditures	$301.0M	$291.0M	-$292.0M
Free Cash Flow	$1.209B	$1.411B	$1.330B
YoY Change	-14.32%	207.41%	-36.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2019Q3	dei	Amendment Flag AmendmentFlag	false
CY2019Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-24
CY2019Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2019Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	D02 XH02
CY2019Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001613103
CY2019Q3	dei	Entity Registrant Name EntityRegistrantName	Medtronic plc
CY2018Q3	mdt	Gain Lossfrom Hedged Firm Commitment Not Qualifyingas Net Investment Hedge Net GainLossfromHedgedFirmCommitmentNotQualifyingasNetInvestmentHedgeNet	0	USD
CY2019Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	190000000	USD
CY2019Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	196000000	USD
CY2018Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.50
CY2019Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.54
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2600000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2600000000	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1340697595	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1340797328	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1340697595	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1340797328	shares
CY2018Q3	us-gaap	Gain Loss From Hedged Firm Commitment Not Qualifying As Fair Value Hedge Net GainLossFromHedgedFirmCommitmentNotQualifyingAsFairValueHedgeNet	0	USD
CY2018Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	500000000	USD
CY2019Q2	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	0	USD
CY2018Q3	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Reductions Securities Sold OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsReductionsSecuritiesSold	0	USD
CY2019Q3	dei	Document Type DocumentType	10-Q
CY2019Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2366000000	USD
CY2019Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Dublin 2
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2204000000	USD
CY2019Q3	dei	Entity Address Country EntityAddressCountry	IE
CY2019Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	587000000	USD
CY2018Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	585000000	USD
CY2019Q3	dei	Country Region CountryRegion	353
CY2019Q3	dei	City Area Code CityAreaCode	1
CY2019Q3	dei	Local Phone Number LocalPhoneNumber	438-1700
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2543000000	USD
CY2019Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019Q3	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2597000000	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	440000000	USD
CY2018Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	446000000	USD
CY2019Q3	dei	Document Period End Date DocumentPeriodEndDate	2019-07-26
CY2019Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2019Q3	dei	Entity File Number EntityFileNumber	001-36820
CY2019Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L2
CY2019Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1183488
CY2019Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	20 On Hatch, Lower Hatch Street
CY2019Q3	dei	Entity Small Business EntitySmallBusiness	false
CY2019Q3	dei	Entity Shell Company EntityShellCompany	false
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1341669471	shares
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7493000000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7384000000	USD
CY2019Q3	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	47000000	USD
CY2018Q3	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	62000000	USD
CY2019Q3	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	47000000	USD
CY2018Q3	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	103000000	USD
CY2019Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	22000000	USD
CY2018Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-151000000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1485000000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1236000000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	101000000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	186000000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	609000000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	242000000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	877000000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	877000000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	1077000000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	1077000000	USD
CY2019Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	13000000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	56000000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2018Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	2000000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	66000000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	864000000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	1075000000	USD
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.64
CY2018Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-824000000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.79
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1351900000	shares
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	977000000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1180000000	USD
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1365400000	shares
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	103000000	USD
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.64
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1340800000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1352700000	shares
CY2019Q3	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	99000000	USD
CY2018Q3	mdt	Other Comprehensive Income Loss Unrealized Gain Loss On Derivatives Arising During Period Net Investment Hedge Net Of Tax OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax	0	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-13000000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-27000000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-7000000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	213000000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	227000000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-584000000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1104000000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	493000000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	13000000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	2000000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1091000000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	491000000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5080000000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4393000000	USD
CY2019Q3	us-gaap	Short Term Investments ShortTermInvestments	5603000000	USD
CY2019Q2	us-gaap	Short Term Investments ShortTermInvestments	5455000000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5894000000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6222000000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	3932000000	USD
CY2019Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1519000000	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1991000000	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1014000000	USD
CY2019Q3	us-gaap	Assets Assets	91268000000	USD
CY2019Q2	us-gaap	Assets Assets	89694000000	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	3753000000	USD
CY2019Q3	us-gaap	Other Assets Current OtherAssetsCurrent	2196000000	USD
CY2019Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2144000000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	22705000000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	21967000000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11136000000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10920000000	USD
CY2019Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6425000000	USD
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6245000000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4711000000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4675000000	USD
CY2019Q3	us-gaap	Goodwill Goodwill	40082000000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	39959000000	USD
CY2019Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20234000000	USD
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20560000000	USD
CY2019Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1545000000	USD
CY2019Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1458000000	USD
CY2019Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	838000000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1906000000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1953000000	USD
CY2019Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1507000000	USD
CY2019Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	2189000000	USD
CY2019Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	500000000	USD
CY2019Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	567000000	USD
CY2019Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3147000000	USD
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2925000000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8518000000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8472000000	USD
CY2019Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	24804000000	USD
CY2019Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	24486000000	USD
CY2019Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1640000000	USD
CY2019Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1651000000	USD
CY2019Q3	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	2873000000	USD
CY2019Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	2838000000	USD
CY2019Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1346000000	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1590000000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	757000000	USD
CY2019Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1278000000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	40771000000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	39482000000	USD
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2019Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26470000000	USD
CY2019Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26532000000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	26377000000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	26270000000	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2484000000	USD
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2711000000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	50363000000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	50091000000	USD
CY2019Q3	us-gaap	Minority Interest MinorityInterest	134000000	USD
CY2019Q2	us-gaap	Minority Interest MinorityInterest	121000000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50497000000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50212000000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	91268000000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89694000000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50212000000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	877000000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	227000000	USD
CY2019Q3	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	724000000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	205000000	USD
CY2019Q3	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	328000000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	61000000	USD
CY2019Q2	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-33000000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50497000000	USD
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50822000000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	1077000000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-584000000	USD
CY2018Q3	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	677000000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	446000000	USD
CY2018Q3	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	820000000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	64000000	USD
CY2018Q3	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	1000000	USD
CY2018Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50329000000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	877000000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	1077000000	USD
CY2019Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	657000000	USD
CY2018Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	666000000	USD
CY2019Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	25000000	USD
CY2018Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	15000000	USD
CY2019Q3	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	18000000	USD
CY2018Q3	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	3000000	USD
CY2019Q3	us-gaap	Share Based Compensation ShareBasedCompensation	61000000	USD
CY2018Q3	us-gaap	Share Based Compensation ShareBasedCompensation	64000000	USD
CY2019Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-406000000	USD
CY2018Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019Q3	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-58000000	USD
CY2018Q3	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3000000	USD
CY2019Q3	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	-319000000	USD
CY2018Q3	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	-138000000	USD
CY2019Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	122000000	USD
CY2018Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	180000000	USD
CY2019Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-629000000	USD
CY2018Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	85000000	USD
CY2019Q3	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	160000000	USD
CY2018Q3	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	169000000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1510000000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1702000000	USD
CY2019Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	145000000	USD
CY2018Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	104000000	USD
CY2019Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	301000000	USD
CY2018Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	291000000	USD
CY2019Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1669000000	USD
CY2018Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	982000000	USD
CY2019Q3	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	1569000000	USD
CY2018Q3	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	2020000000	USD
CY2019Q3	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	5000000	USD
CY2018Q3	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-551000000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	643000000	USD
CY2019Q3	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	88000000	USD
CY2018Q3	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	-505000000	USD
CY2019Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5567000000	USD
CY2018Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2019Q3	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	5035000000	USD
CY2018Q3	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	12000000	USD
CY2019Q3	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	724000000	USD
CY2018Q3	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	677000000	USD
CY2019Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	210000000	USD
CY2018Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	450000000	USD
CY2019Q3	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	333000000	USD
CY2018Q3	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	824000000	USD
CY2019Q3	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-47000000	USD
CY2018Q3	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-5000000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-274000000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1573000000	USD
CY2019Q3	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2000000	USD
CY2018Q3	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-61000000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	687000000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	711000000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4393000000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3669000000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5080000000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4380000000	USD
CY2019Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	198000000	USD
CY2018Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	348000000	USD
CY2019Q3	us-gaap	Interest Paid Net InterestPaidNet	86000000	USD
CY2018Q3	us-gaap	Interest Paid Net InterestPaidNet	55000000	USD
CY2019Q3	us-gaap	Basis Of Accounting BasisOfAccounting	<span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all of the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation. </span></div><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements of the Company and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">April 26, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company’s fiscal years </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> will end or ended on </span><span style="font-family:inherit;font-size:10pt;">April 24, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">April 26, 2019</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">April 27, 2018</span>, respectively.
CY2019Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	222000000	USD
CY2019Q3	us-gaap	Fiscal Period FiscalPeriod	The Company’s fiscal years <span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> will end or ended on </span><span style="font-family:inherit;font-size:10pt;">April 24, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">April 26, 2019</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">April 27, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span>
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7493000000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7384000000	USD
CY2019Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	295000000	USD
CY2019Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	315000000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	98000000	USD
CY2019Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1000000000.0	USD
CY2019Q3	us-gaap	Revenue Performance Obligation Description Of Timing RevenuePerformanceObligationDescriptionOfTiming	four years
CY2019Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	269000000	USD
CY2019Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	222000000	USD
CY2018Q3	mdt	Business Acquisition Purchase Price Contingent Consideration BusinessAcquisitionPurchasePriceContingentConsideration	35000000	USD
CY2018Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	173000000	USD
CY2019Q3	mdt	Business Acquisition Purchase Price Contingent Consideration BusinessAcquisitionPurchasePriceContingentConsideration	58000000	USD
CY2019Q3	mdt	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	14000000	USD
CY2018Q3	mdt	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	6000000	USD
CY2019Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3000000	USD
CY2018Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-6000000	USD
CY2019Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	269000000	USD
CY2018Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	208000000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	5633000000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	49000000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	35000000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	5647000000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	5540000000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	20000000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	61000000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	5499000000	USD
CY2019Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	872000000	USD
CY2019Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	11000000	USD
CY2019Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	951000000	USD
CY2019Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	24000000	USD
CY2019Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	1075000000	USD
CY2019Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	9000000	USD
CY2019Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	2181000000	USD
CY2019Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	52000000	USD
CY2019Q3	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1567000000	USD
CY2018Q3	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1112000000	USD
CY2019Q3	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	4000000	USD
CY2018Q3	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	6000000	USD
CY2019Q3	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	8000000	USD
CY2018Q3	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	7000000	USD
CY2019Q3	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	0	USD
CY2019Q3	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Reductions Securities Sold OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsReductionsSecuritiesSold	0	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1157000000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	2407000000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	2030000000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	53000000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	5647000000	USD
CY2019Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
CY2019Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1458000000	USD
CY2019Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	838000000	USD
CY2019Q3	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	16000000	USD
CY2019Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	-29000000	USD
CY2019Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	116000000	USD
CY2019Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	104000000	USD
CY2019Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	24804000000	USD
CY2019Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	24486000000	USD
CY2019Q3	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	27800000000	USD
CY2019Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	25900000000	USD
CY2019Q2	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	26200000000	USD
CY2019Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	25000000000.0	USD
CY2019Q3	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-1000000	USD
CY2018Q3	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	141000000	USD
CY2019Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	22000000	USD
CY2018Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-151000000	USD
CY2019Q3	mdt	Unrealized Gain Loss On Interest Rate Cash Flow Hedges Accumulated Other Comprehensive Income Loss Net Of Tax UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax	187000000	USD
CY2019Q2	mdt	Unrealized Gain Loss On Interest Rate Cash Flow Hedges Accumulated Other Comprehensive Income Loss Net Of Tax UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax	194000000	USD
CY2019Q3	us-gaap	Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths	164000000	USD
CY2019Q3	us-gaap	Gain Loss From Hedged Firm Commitment Not Qualifying As Fair Value Hedge Net GainLossFromHedgedFirmCommitmentNotQualifyingAsFairValueHedgeNet	0	USD
CY2019Q3	mdt	Unrealized Gain Losson Net Investment Hedges Accumulated Other Comprehensive Income Loss Netof Tax UnrealizedGainLossonNetInvestmentHedgesAccumulatedOtherComprehensiveIncomeLossNetofTax	-70000000	USD
CY2018Q3	mdt	Unrealized Gain Losson Net Investment Hedges Accumulated Other Comprehensive Income Loss Netof Tax UnrealizedGainLossonNetInvestmentHedgesAccumulatedOtherComprehensiveIncomeLossNetofTax	-169000000	USD
CY2019Q3	mdt	Net Investment Hedge Gain Losstobe Reclassified Within Twelve Months NetInvestmentHedgeGainLosstobeReclassifiedWithinTwelveMonths	0	USD
CY2019Q3	mdt	Gain Lossfrom Hedged Firm Commitment Not Qualifyingas Net Investment Hedge Net GainLossfromHedgedFirmCommitmentNotQualifyingasNetInvestmentHedgeNet	0	USD
CY2019Q3	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	318000000	USD
CY2019Q3	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	33000000	USD
CY2019Q2	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	365000000	USD
CY2019Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	19000000	USD
CY2019Q3	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	318000000	USD
CY2019Q3	us-gaap	Derivative Asset Not Offset Policy Election Deduction DerivativeAssetNotOffsetPolicyElectionDeduction	19000000	USD
CY2019Q3	us-gaap	Derivative Collateral Obligation To Return Cash DerivativeCollateralObligationToReturnCash	5000000	USD
CY2019Q3	us-gaap	Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral	294000000	USD
CY2019Q3	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	33000000	USD
CY2019Q3	us-gaap	Derivative Liability Not Offset Policy Election Deduction DerivativeLiabilityNotOffsetPolicyElectionDeduction	19000000	USD
CY2019Q3	us-gaap	Derivative Collateral Right To Reclaim Cash DerivativeCollateralRightToReclaimCash	0	USD
CY2019Q3	us-gaap	Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral	14000000	USD
CY2019Q3	mdt	Derivative Asset Liability Fair Value Gross Asset Liability DerivativeAssetLiabilityFairValueGrossAssetLiability	285000000	USD
CY2019Q3	mdt	Derivative Assetsand Liabilities Net Not Offset Policy Election Deduction DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction	0	USD
CY2019Q3	mdt	Derivative Assetsand Liabilities Net Collateral Obligationto Return Cash DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash	5000000	USD
CY2019Q3	us-gaap	Derivative Fair Value Amount Offset Against Collateral Net DerivativeFairValueAmountOffsetAgainstCollateralNet	280000000	USD
CY2019Q2	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	365000000	USD
CY2019Q2	us-gaap	Derivative Asset Not Offset Policy Election Deduction DerivativeAssetNotOffsetPolicyElectionDeduction	9000000	USD
CY2019Q2	us-gaap	Derivative Collateral Obligation To Return Cash DerivativeCollateralObligationToReturnCash	44000000	USD
CY2019Q2	us-gaap	Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral	312000000	USD
CY2019Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	19000000	USD
CY2019Q2	us-gaap	Derivative Liability Not Offset Policy Election Deduction DerivativeLiabilityNotOffsetPolicyElectionDeduction	9000000	USD
CY2019Q2	us-gaap	Derivative Collateral Right To Reclaim Cash DerivativeCollateralRightToReclaimCash	0	USD
CY2019Q2	us-gaap	Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral	10000000	USD
CY2019Q2	mdt	Derivative Asset Liability Fair Value Gross Asset Liability DerivativeAssetLiabilityFairValueGrossAssetLiability	346000000	USD
CY2019Q2	mdt	Derivative Assetsand Liabilities Net Not Offset Policy Election Deduction DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction	0	USD
CY2019Q2	mdt	Derivative Assetsand Liabilities Net Collateral Obligationto Return Cash DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash	44000000	USD
CY2019Q2	us-gaap	Derivative Fair Value Amount Offset Against Collateral Net DerivativeFairValueAmountOffsetAgainstCollateralNet	302000000	USD
CY2019Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2628000000	USD
CY2019Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2476000000	USD
CY2019Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	569000000	USD
CY2019Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	572000000	USD
CY2019Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	735000000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9048000000	USD
CY2019Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	705000000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	3932000000	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	3753000000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	39959000000	USD
CY2019Q3	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	65000000	USD
CY2019Q3	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	5000000	USD
CY2019Q3	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	53000000	USD
CY2019Q3	us-gaap	Goodwill Goodwill	40082000000	USD
CY2019Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	28298000000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8667000000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29004000000	USD
CY2019Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2018Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	61000000	USD
CY2019Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	440000000	USD
CY2018Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	446000000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1315000000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1738000000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1698000000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1630000000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1593000000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1560000000	USD
CY2019Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.102
CY2018Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.087
CY2019Q3	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	-30000000	USD
CY2019Q3	us-gaap	Tax Cuts And Jobs Act Of2017 Measurement Period Adjustment Income Tax Expense Benefit TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit	-30000000	USD
CY2018Q3	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	-29000000	USD
CY2018Q3	us-gaap	Tax Cuts And Jobs Act Of2017 Measurement Period Adjustment Income Tax Expense Benefit TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit	-50000000	USD
CY2018Q3	us-gaap	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Expense TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense	21000000	USD
CY2019Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1900000000	USD
CY2019Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1800000000	USD
CY2019Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	186000000	USD
CY2019Q3	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1800000000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	864000000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1075000000	USD
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1340800000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1352700000	shares
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	6900000	shares
CY2018Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	8400000	shares
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	3500000	shares
CY2018Q3	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	3600000	shares
CY2019Q3	mdt	Incremental Common Shares Attributableto Dilutive Effectof Other Shares IncrementalCommonSharesAttributabletoDilutiveEffectofOtherShares	700000	shares
CY2018Q3	mdt	Incremental Common Shares Attributableto Dilutive Effectof Other Shares IncrementalCommonSharesAttributabletoDilutiveEffectofOtherShares	700000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1351900000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1365400000	shares
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.64
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.79
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.64
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	61000000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	64000000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	61000000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	64000000	USD
CY2019Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	10000000	USD
CY2018Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	11000000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	51000000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	53000000	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	948000000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	183000000	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	795000000	USD
CY2019Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y6M
CY2019Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.030
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	55000000	USD
CY2019Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	11000000	USD
CY2019Q3	us-gaap	Lease Cost LeaseCost	66000000	USD
CY2019Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	57000000	USD
CY2019Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	49000000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	152000000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	184000000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	153000000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	132000000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	111000000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	432000000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1164000000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	186000000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	978000000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	216000000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	157000000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	103000000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	61000000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	34000000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	81000000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	652000000	USD
CY2019Q3	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<span style="font-weight:bold;"> Commitments and Contingencies</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Matters</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, income tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. At </span><span style="font-family:inherit;font-size:10pt;">July 26, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">April 26, 2019</span><span style="font-family:inherit;font-size:10pt;">, accrued litigation was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 billion</span></span><span style="font-family:inherit;font-size:10pt;">. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">other accrued expenses</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">other liabilities</span><span style="font-family:inherit;font-size:10pt;"> on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Liability Matters</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Pelvic Mesh Litigation</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. </span><span style="font-family:inherit;font-size:10pt;"><span>Two</span></span><span style="font-family:inherit;font-size:10pt;"> subsidiaries of Covidien supplied pelvic mesh products to </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In fiscal year 2016, Bard paid the Company </span><span style="font-family:inherit;font-size:10pt;"><span>$121 million</span></span><span style="font-family:inherit;font-size:10pt;"> towards </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the settlement of </span><span style="font-family:inherit;font-size:10pt;"><span>11,000</span></span><span style="font-family:inherit;font-size:10pt;"> of these claims. In May 2017, the agreement with Bard was amended to extend the terms to apply to up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>5,000</span></span><span style="font-family:inherit;font-size:10pt;"> claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately </span><span style="font-family:inherit;font-size:10pt;"><span>15,800</span></span><span style="font-family:inherit;font-size:10pt;"> claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of August 7, 2019, the Company had reached agreements to settle approximately </span><span style="font-family:inherit;font-size:10pt;"><span>15,400</span></span><span style="font-family:inherit;font-size:10pt;"> of these claims. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Patent Litigation</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Ethicon</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 14, 2011, Ethicon filed an action against Covidien in the U.S. District Court for the Southern District of Ohio, alleging patent infringement and seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien's favor, and the majority of this ruling was affirmed by the Federal Circuit on August 7, 2015. Following appeal, the case was remanded back to the District Court with respect to </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> patent. On January 21, 2016, Covidien filed a second action in the U.S. District Court for the Southern District of Ohio, seeking a declaration of non-infringement with respect to a second set of patents held by Ethicon. The court consolidated this second action with the remaining patent issues from the first action. Following consolidation of the cases, Ethicon dismissed </span><span style="font-family:inherit;font-size:10pt;"><span>six</span></span><span style="font-family:inherit;font-size:10pt;"> of the asserted patents, leaving a single asserted patent. In addition to claims of non-infringement, the Company asserts an affirmative defense of invalidity. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sasso</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is involved in litigation in Indiana relating to certain patent and royalty disputes with Dr. Sasso under agreements originally entered into in 1999 and 2001. On November 28, 2018, a jury in Indiana state court returned a verdict against the Company for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$112 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company has strong arguments to appeal the verdict and has filed post-trial motions and appeals with the appropriate appellate courts. The Company has not recognized an expense in connection with this matter because it does not currently believe a loss is probable under U.S. GAAP. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Shareholder Related Matters</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Covidien Acquisition</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. Board of Directors at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September 2014, the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Merenstein</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Steiner</span><span style="font-family:inherit;font-size:10pt;"> matters were consolidated and in December 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On March 20, 2015, the District Court issued an order and opinion granting Medtronic’s motion to dismiss the case. In May of 2015, the plaintiffs filed an appeal, and, in January of 2016, the Minnesota State Court of Appeals affirmed in part, and reversed in part. On April 19, 2016 the Minnesota Supreme Court granted the Company’s petition to review the issue of whether most of the original claims are properly characterized as direct or derivative under Minnesota law. In August of 2017, the Minnesota Supreme Court affirmed the decision of the Minnesota State Court of Appeals, sending the matter back to the trial court for further proceedings, which are ongoing. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Environmental Proceedings</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008, which included a directive to remove a significant volume of soils at the site. After a hearing on the compliance order before the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order, the Maine Board modified the MDEP order and issued a final order requiring removal of </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> landfills, capping of the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> landfills, installation of a groundwater extraction system and long-term monitoring of the site and the </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> remaining landfills.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since the early 2000s, the Company or its predecessors have also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring the Company's predecessor to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following a trial in March 2002, the Court held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that the Company’s predecessor was liable for the cost of performing a study of the River and Bay. Following a second trial in June 2014, the Court ordered that further engineering study and engineering design work was needed to determine the nature and extent of remediation in the Penobscot River and Bay. The Court also appointed an engineering firm to conduct such studies and issue a report on potential remediation alternatives. In connection with these proceedings, reports have been produced including a variety of cost estimates for a variety of potential remedial options. A third trial to determine the course of remediation to be pursued is scheduled to occur in February of 2020.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's accrued expenses for environmental proceedings are included within accrued litigation as discussed above. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Government Matters</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since 2017, the Company has been responding to requests from the Department of Justice and U.S. Department of Health and Human Services for information about business practices relating to a neurovascular product developed and first marketed by ev3 and Covidien. The Company has provided information in response to these requests and is cooperating with the inquiry. The Company has not recognized an expense in connection with any ongoing investigation, because any such potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from the ongoing information requests. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court reviewed this dispute, and on June 9, 2016, issued its opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006. The U.S. Tax Court generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. On April 21, 2017, the IRS filed their Notice of Appeal to the U.S. Court of Appeals for the 8th Circuit regarding the Tax Court Opinion. Oral argument for the Appeal occurred on March 14, 2018. The 8th Circuit Court of Appeals issued their opinion on August 16, 2018, and remanded the case back to the U.S. Tax Court for additional factual findings. U.S. Tax Court trial is scheduled to occur in April of 2020.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2007 and 2008 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2009, 2010, and 2011 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2012, 2013, and 2014. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, and proposed </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">adjustments associated with the utilization of certain net operating losses. The Company disagrees with the IRS and will attempt to resolve these matters at the IRS Appellate level.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medtronic, Inc.’s fiscal years 2015 and 2016 U.S. federal income tax returns are currently being audited by the IRS.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for all tax years through 2012. The statute of limitations for Covidien’s 2013 and 2014 U.S. federal income tax returns lapsed during the first quarter of fiscal years 2018 and 2019, respectively. Covidien's fiscal year 2015 U.S. federal income tax returns are currently being audited by the IRS.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to Note </span><span style="font-family:inherit;font-size:10pt;">11</span><span style="font-family:inherit;font-size:10pt;"> for additional discussion of income taxes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Guarantees</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the acquisition of Covidien, the Company has a guarantee commitment related to certain contingent tax liabilities as a party to the Tax Sharing Agreement that was entered into on June 29, 2007, between Covidien, Tyco International (now Johnson Controls), and Tyco Electronics (now TE Connectivity), associated with the spin-off from Tyco. The Tax Sharing Agreement covers certain income tax liabilities for periods prior to and including the spin-off. Medtronic’s share of the income tax liabilities for these periods is </span><span style="font-family:inherit;font-size:10pt;"><span>42 percent</span></span><span style="font-family:inherit;font-size:10pt;">, with Johnson Controls and TE Connectivity share being </span><span style="font-family:inherit;font-size:10pt;"><span>27 percent</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>31 percent</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. If Johnson Controls and TE Connectivity default on their obligations to the Company under the Tax Sharing Agreement, the Company would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties. The most significant amounts at risk under this Tax Sharing Agreement were resolved with the U.S. Tax Court and IRS Appeals resolutions reached in May 2016. However, the Tax Sharing Agreement remains in place with respect to income tax liabilities that are not the subject of such resolution, including certain state and international tax matters that remain open.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has used available information to develop its best estimates for certain assets and liabilities related to periods prior to the 2007 separation, including amounts subject to or impacted by the provisions of the Tax Sharing Agreement. The actual amounts that the Company may be required to ultimately accrue or pay under the Tax Sharing Agreement, however, could vary depending upon the outcome of the unresolved tax matters. Final determination of the balances will be made in subsequent periods, primarily related to tax years that remain open for examination. These balances will also be impacted by the filing of final or amended income tax returns in certain jurisdictions where those returns include a combination of Tyco International, Covidien and/or Tyco Electronics legal entities for periods prior to the 2007 separation.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to Note 1 </span><span style="font-family:inherit;font-size:10pt;">to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2019</span><span style="font-family:inherit;font-size:10pt;"> for additional information.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the Company’s sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal on July 29, 2017, the Company has indemnified Cardinal for certain contingent tax liabilities related to the divested businesses that existed prior to the date of divestiture. The actual amounts that the Company may be required to ultimately accrue or pay could vary depending upon the outcome of the unresolved tax matters.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates’ products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company’s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company’s consolidated earnings, financial position, or cash flows.</span></div>
CY2019Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	500000000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7493000000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7384000000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	977000000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1180000000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7493000000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7384000000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7493000000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2366000000	USD
CY2019Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	587000000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2543000000	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	440000000	USD
CY2019Q3	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	47000000	USD
CY2019Q3	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	47000000	USD
CY2019Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	22000000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1485000000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	101000000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	609000000	USD
CY2019Q3	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	977000000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	877000000	USD
CY2019Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	13000000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	864000000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	227000000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	13000000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1091000000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7384000000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2204000000	USD
CY2018Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	585000000	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2597000000	USD
CY2018Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	446000000	USD
CY2018Q3	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	62000000	USD
CY2018Q3	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	103000000	USD
CY2018Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-151000000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1236000000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	186000000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	242000000	USD
CY2018Q3	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1180000000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	103000000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	1077000000	USD
CY2018Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	2000000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	1075000000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-584000000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	2000000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	491000000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5080000000	USD
CY2019Q3	us-gaap	Short Term Investments ShortTermInvestments	5603000000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5894000000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	3932000000	USD
CY2019Q3	mdt	Intercompany Receivable Current IntercompanyReceivableCurrent	0	USD
CY2019Q3	us-gaap	Other Assets Current OtherAssetsCurrent	2196000000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	22705000000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4711000000	USD
CY2019Q3	us-gaap	Goodwill Goodwill	40082000000	USD
CY2019Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20234000000	USD
CY2019Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1545000000	USD
CY2019Q3	mdt	Investmentin Subsidiaries InvestmentinSubsidiaries	0	USD
CY2019Q3	mdt	Intercompany Receivable Noncurrent IntercompanyReceivableNoncurrent	0	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1991000000	USD
CY2019Q3	us-gaap	Assets Assets	91268000000	USD
CY2019Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1458000000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1906000000	USD
CY2019Q3	mdt	Intercompany Payable Current IntercompanyPayableCurrent	0	USD
CY2019Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1507000000	USD
CY2019Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	500000000	USD
CY2019Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3147000000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8518000000	USD
CY2019Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	24804000000	USD
CY2019Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1640000000	USD
CY2019Q3	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	2873000000	USD
CY2019Q3	mdt	Intercompany Payable Noncurrent IntercompanyPayableNoncurrent	0	USD
CY2019Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1346000000	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1590000000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	40771000000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	50363000000	USD
CY2019Q3	us-gaap	Minority Interest MinorityInterest	134000000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50497000000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	91268000000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4393000000	USD
CY2019Q2	us-gaap	Short Term Investments ShortTermInvestments	5455000000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6222000000	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	3753000000	USD
CY2019Q2	mdt	Intercompany Receivable Current IntercompanyReceivableCurrent	0	USD
CY2019Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2144000000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	21967000000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4675000000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	39959000000	USD
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20560000000	USD
CY2019Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1519000000	USD
CY2019Q2	mdt	Investmentin Subsidiaries InvestmentinSubsidiaries	0	USD
CY2019Q2	mdt	Intercompany Receivable Noncurrent IntercompanyReceivableNoncurrent	0	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1014000000	USD
CY2019Q2	us-gaap	Assets Assets	89694000000	USD
CY2019Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	838000000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1953000000	USD
CY2019Q2	mdt	Intercompany Payable Current IntercompanyPayableCurrent	0	USD
CY2019Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	2189000000	USD
CY2019Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	567000000	USD
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2925000000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8472000000	USD
CY2019Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	24486000000	USD
CY2019Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1651000000	USD
CY2019Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	2838000000	USD
CY2019Q2	mdt	Intercompany Payable Noncurrent IntercompanyPayableNoncurrent	0	USD
CY2019Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1278000000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	757000000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	39482000000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	50091000000	USD
CY2019Q2	us-gaap	Minority Interest MinorityInterest	121000000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50212000000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89694000000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1510000000	USD
CY2019Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	145000000	USD
CY2019Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	301000000	USD
CY2019Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1669000000	USD
CY2019Q3	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	1569000000	USD
CY2019Q3	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	5000000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-551000000	USD
CY2019Q3	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	88000000	USD
CY2019Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5567000000	USD
CY2019Q3	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	5035000000	USD
CY2019Q3	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	724000000	USD
CY2019Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	210000000	USD
CY2019Q3	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	333000000	USD
CY2019Q3	mdt	Increase Decreasein Intercompany Payable IncreaseDecreaseinIntercompanyPayable	0	USD
CY2019Q3	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-47000000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-274000000	USD
CY2019Q3	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2000000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	687000000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4393000000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5080000000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1702000000	USD
CY2018Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	104000000	USD
CY2018Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	291000000	USD
CY2018Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	982000000	USD
CY2018Q3	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	2020000000	USD
CY2018Q3	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	643000000	USD
CY2018Q3	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	-505000000	USD
CY2018Q3	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	12000000	USD
CY2018Q3	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	677000000	USD
CY2018Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	450000000	USD
CY2018Q3	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	824000000	USD
CY2018Q3	mdt	Increase Decreasein Intercompany Payable IncreaseDecreaseinIntercompanyPayable	0	USD
CY2018Q3	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0	USD
CY2018Q3	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-5000000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1573000000	USD
CY2018Q3	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-61000000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	711000000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3669000000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4380000000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7493000000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2366000000	USD
CY2019Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	587000000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2543000000	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	440000000	USD
CY2019Q3	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	47000000	USD
CY2019Q3	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	47000000	USD
CY2019Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	22000000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1485000000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	101000000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	609000000	USD
CY2019Q3	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	977000000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	877000000	USD
CY2019Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	13000000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	864000000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	227000000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	13000000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1091000000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7384000000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2204000000	USD
CY2018Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	585000000	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2597000000	USD
CY2018Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	446000000	USD
CY2018Q3	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	62000000	USD
CY2018Q3	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	103000000	USD
CY2018Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-151000000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1236000000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	186000000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	242000000	USD
CY2018Q3	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1180000000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	103000000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	1077000000	USD
CY2018Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	2000000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	1075000000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-584000000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	2000000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	491000000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5080000000	USD
CY2019Q3	us-gaap	Short Term Investments ShortTermInvestments	5603000000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5894000000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	3932000000	USD
CY2019Q3	mdt	Intercompany Receivable Current IntercompanyReceivableCurrent	0	USD
CY2019Q3	us-gaap	Other Assets Current OtherAssetsCurrent	2196000000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	22705000000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4711000000	USD
CY2019Q3	us-gaap	Goodwill Goodwill	40082000000	USD
CY2019Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20234000000	USD
CY2019Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1545000000	USD
CY2019Q3	mdt	Investmentin Subsidiaries InvestmentinSubsidiaries	0	USD
CY2019Q3	mdt	Intercompany Receivable Noncurrent IntercompanyReceivableNoncurrent	0	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1991000000	USD
CY2019Q3	us-gaap	Assets Assets	91268000000	USD
CY2019Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1458000000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1906000000	USD
CY2019Q3	mdt	Intercompany Payable Current IntercompanyPayableCurrent	0	USD
CY2019Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1507000000	USD
CY2019Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	500000000	USD
CY2019Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3147000000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8518000000	USD
CY2019Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	24804000000	USD
CY2019Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1640000000	USD
CY2019Q3	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	2873000000	USD
CY2019Q3	mdt	Intercompany Payable Noncurrent IntercompanyPayableNoncurrent	0	USD
CY2019Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1346000000	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1590000000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	40771000000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	50363000000	USD
CY2019Q3	us-gaap	Minority Interest MinorityInterest	134000000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50497000000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	91268000000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4393000000	USD
CY2019Q2	us-gaap	Short Term Investments ShortTermInvestments	5455000000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6222000000	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	3753000000	USD
CY2019Q2	mdt	Intercompany Receivable Current IntercompanyReceivableCurrent	0	USD
CY2019Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2144000000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	21967000000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4675000000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	39959000000	USD
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20560000000	USD
CY2019Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1519000000	USD
CY2019Q2	mdt	Investmentin Subsidiaries InvestmentinSubsidiaries	0	USD
CY2019Q2	mdt	Intercompany Receivable Noncurrent IntercompanyReceivableNoncurrent	0	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1014000000	USD
CY2019Q2	us-gaap	Assets Assets	89694000000	USD
CY2019Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	838000000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1953000000	USD
CY2019Q2	mdt	Intercompany Payable Current IntercompanyPayableCurrent	0	USD
CY2019Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	2189000000	USD
CY2019Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	567000000	USD
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2925000000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8472000000	USD
CY2019Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	24486000000	USD
CY2019Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1651000000	USD
CY2019Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	2838000000	USD
CY2019Q2	mdt	Intercompany Payable Noncurrent IntercompanyPayableNoncurrent	0	USD
CY2019Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1278000000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	757000000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	39482000000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	50091000000	USD
CY2019Q2	us-gaap	Minority Interest MinorityInterest	121000000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50212000000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89694000000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1510000000	USD
CY2019Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	145000000	USD
CY2019Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	301000000	USD
CY2019Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1669000000	USD
CY2019Q3	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	1569000000	USD
CY2019Q3	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	USD
CY2019Q3	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	5000000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-551000000	USD
CY2019Q3	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	88000000	USD
CY2019Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5567000000	USD
CY2019Q3	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	5035000000	USD
CY2019Q3	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	724000000	USD
CY2019Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	210000000	USD
CY2019Q3	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	333000000	USD
CY2018Q3	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	2020000000	USD
CY2018Q3	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	643000000	USD
CY2018Q3	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	-505000000	USD
CY2018Q3	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	12000000	USD
CY2019Q3	mdt	Increase Decreasein Intercompany Payable IncreaseDecreaseinIntercompanyPayable	0	USD
CY2019Q3	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0	USD
CY2019Q3	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-47000000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-274000000	USD
CY2019Q3	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2000000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	687000000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4393000000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5080000000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1702000000	USD
CY2018Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	104000000	USD
CY2018Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	291000000	USD
CY2018Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	982000000	USD
CY2018Q3	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	677000000	USD
CY2018Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	450000000	USD
CY2018Q3	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	824000000	USD
CY2018Q3	mdt	Increase Decreasein Intercompany Payable IncreaseDecreaseinIntercompanyPayable	0	USD
CY2018Q3	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0	USD
CY2018Q3	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-5000000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1573000000	USD
CY2018Q3	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-61000000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	711000000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3669000000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4380000000	USD

Files In Submission

Name	View Source	Status
0001613103-19-000038-index-headers.html	Edgar Link	pending
0001613103-19-000038-index.html	Edgar Link	pending
0001613103-19-000038.txt	Edgar Link	pending
0001613103-19-000038-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mdt-20190726.xsd	Edgar Link	pending
mdt-20190726_cal.xml	Edgar Link	unprocessable
mdt-20190726_def.xml	Edgar Link	unprocessable
mdt-20190726_lab.xml	Edgar Link	unprocessable
mdt-20190726_pre.xml	Edgar Link	unprocessable
mdt-2020q1x10q.htm	Edgar Link	pending
mdt-2020q1x10q_htm.xml	Edgar Link	completed
mdt-2020q1xex311.htm	Edgar Link	pending
mdt-2020q1xex312.htm	Edgar Link	pending
mdt-2020q1xex321.htm	Edgar Link	pending
mdt-2020q1xex322.htm	Edgar Link	pending
mdtlogo2a94.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDT
Medtronic plc Stock $mdt

2019 Q3 Form 10-Q Financial Statement

#000161310319000038 Filed on August 30, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDT Medtronic plc Stock $mdt

2019 Q3 Form 10-Q Financial Statement

#000161310319000038 Filed on August 30, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDT
Medtronic plc Stock $mdt